Celgene Corporation (CELG) Stake Lessened by Investec Asset Management North America Inc.
Investec Asset Management North America Inc. cut its stake in shares of Celgene Corporation (NASDAQ:CELG) by 6.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,260 shares of the biopharmaceutical company’s stock after selling 6,249 shares during the period. Celgene Corporation makes up about 2.0% of Investec Asset Management North America Inc.’s holdings, making the stock its 26th biggest position. Investec Asset Management North America Inc.’s holdings in Celgene Corporation were worth $11,073,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Thompson Davis & CO. Inc. raised its position in Celgene Corporation by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the period. Motco raised its position in Celgene Corporation by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the period. Penserra Capital Management LLC acquired a new position in Celgene Corporation during the second quarter valued at $129,000. Acropolis Investment Management LLC acquired a new position in Celgene Corporation during the second quarter valued at $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the period. 79.48% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Celgene Corporation (NASDAQ CELG) opened at $105.16 on Thursday. The stock has a market capitalization of $82,274.63, a PE ratio of 16.33, a PEG ratio of 0.81 and a beta of 1.79. Celgene Corporation has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.58 EPS. research analysts expect that Celgene Corporation will post 6.67 earnings per share for the current year.
Several research analysts recently weighed in on the company. Cann reissued a “buy” rating and set a $166.00 price target on shares of Celgene Corporation in a research report on Wednesday. TheStreet lowered Celgene Corporation from a “b-” rating to a “c+” rating in a research report on Friday, November 17th. BMO Capital Markets upped their price target on Celgene Corporation from $148.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, November 17th. Canaccord Genuity set a $140.00 target price on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, November 16th. Finally, Oppenheimer Holdings, Inc. set a $166.00 target price on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $139.57.
TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/23/celgene-corporation-celg-stake-lessened-by-investec-asset-management-north-america-inc.html.
In other news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is currently owned by corporate insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.